Inhibition of ADAMTS1 and ATP citrate lyase attenuates connexin-43 degradation and HFrEF

Yu-Ting Zheng1, Suresh C Tyagi1

  • 1Department of Physiology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.

Insights

Heart failure with reduced ejection fraction (HFrEF) involves connexin-43 (Cx43) degradation and mitochondrial issues. Inhibiting ADAMTS1 or ACYLi may offer therapeutic benefits for HFrEF.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • 56% of heart failure cases have unknown causes, with ADAMTS implicated.
  • Connexin-43 (Cx43) degradation and blood-heart barrier leakage occur in heart failure with reduced ejection fraction (HFrEF).
  • The role of mitochondrial ATP citrate lyase (ACYL) in HFrEF is unknown, though its inhibition causes HFpEF.

Purpose of the Study:

  • To investigate the role of ADAMTS1 in Cx43 degradation and mitochondrial dysfunction during HFrEF.
  • To explore the therapeutic potential of ADAMTS1 and ACYL inhibitors in HFrEF.

Main Methods:

  • Created a mouse model of HFrEF using aorta-vena cava fistula (AVF).
  • Administered ADAMTS1 inhibitor (epigallocatechin gallate) or ACYLi (hydroxycitric acid lactone) to mice.
  • Assessed cardiac function via echocardiography and measured protein levels (Cx43, ADAMTS1, Drp1, ACYL) using Western blot and zymography.

Main Results:

  • ADAMTS1 activation was observed during HFrEF.
  • Increased Cx43 degradation and mitochondrial mitophagy (via Drp1 increase) were linked to HFrEF.
  • Both ADAMTS1 and ACYL inhibitors showed potential therapeutic effects in systolic HFrEF.

Conclusions:

  • ADAMTS1 activation contributes to Cx43 degradation and mitochondrial dysfunction in HFrEF.
  • Inhibitors of ADAMTS1 and ACYL represent potential therapeutic strategies for HFrEF.

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
44.2K
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
16.0K
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
13.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
642